1KPA Stock Chart & Stats
€4.15
€0.30(5.45%)
At close: 4:00 PM EST
€4.15
€0.30(5.45%)
Day’s Range― - ―
52-Week Range€2.48 - €6.50
Previous CloseN/A
Volume2.27K
Average Volume (3M)436.00
Market Cap
€202.15M
Enterprise Value€145.38M
Total Cash (Recent Filing)€135.79M
Total Debt (Recent Filing)€3.06M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Jul 30, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding56,204,240
10 Day Avg. Volume0
30 Day Avg. Volume436
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-4.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.80Price Target Upside449.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity BaseVery low leverage gives the company financial flexibility to fund R&D and absorb setbacks without interest burden. A materially larger equity base since 2023 improves solvency and supports additional financing options, reducing near-term liquidity crisis risk for a clinical-stage biotech.
Improved Financing FlexibilityDoubling authorized shares and amending the equity incentive plan increases the company’s ability to raise capital and use equity for partnerships or M&A. For a pre-revenue biotech, expanded capital flexibility is a durable enabler of continued development funding and strategic optionality.
Clinical Leadership ContinuityAlthough the CMO departed, responsibilities shifted to the lead medical director with oversight from the Chief R&D Officer, supporting operational continuity. Maintaining internal clinical leadership reduces execution risk for ongoing trials and preserves institutional knowledge during development milestones.
Bears Say
No Revenue / Recurring LossesAs a clinical-stage firm with essentially zero revenue, the company cannot self-fund operations and remains fully dependent on external capital. Persistent operating and net losses mean value creation hinges on successful clinical readouts or partnerships, raising binary outcome risk for investors.
Consistent Negative Cash Flow And Rising BurnSustained negative operating and free cash flow with rising burn materially shortens runway absent financing. This structural cash dependence forces frequent capital raises, which can dilute shareholders and constrain long-term planning, limiting ability to pursue parallel development programs.
Dilution Risk From Capital Structure ChangesWhile expanding authorized shares aids financing, it also increases the likelihood of future dilution via share issuance or broader equity compensation. For a non-revenue biotech, repeated dilutive financings can erode per-share economics and reduce long-term investor returns if development milestones underperform.
Protara Therapeutics News
1KPA FAQ
What was Protara Therapeutics, Inc.’s price range in the past 12 months?
Protara Therapeutics, Inc. lowest stock price was €2.48 and its highest was €6.50 in the past 12 months.
What is Protara Therapeutics, Inc.’s market cap?
Protara Therapeutics, Inc.’s market cap is €202.15M.
When is Protara Therapeutics, Inc.’s upcoming earnings report date?
Protara Therapeutics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 21 days.
How were Protara Therapeutics, Inc.’s earnings last quarter?
Protara Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -€0.271 earnings per share for the quarter, beating the consensus estimate of -€0.323 by €0.052.
Is Protara Therapeutics, Inc. overvalued?
According to Wall Street analysts Protara Therapeutics, Inc.’s price is currently Undervalued.
Does Protara Therapeutics, Inc. pay dividends?
Protara Therapeutics, Inc. does not currently pay dividends.
What is Protara Therapeutics, Inc.’s EPS estimate?
Protara Therapeutics, Inc.’s EPS estimate is -0.29.
How many shares outstanding does Protara Therapeutics, Inc. have?
Protara Therapeutics, Inc. has 56,204,240 shares outstanding.
What happened to Protara Therapeutics, Inc.’s price movement after its last earnings report?
Protara Therapeutics, Inc. reported an EPS of -€0.271 in its last earnings report, beating expectations of -€0.323. Following the earnings report the stock price went down -1.221%.
Which hedge fund is a major shareholder of Protara Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DE:1KPA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protara Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€22.80 (449.30% Upside)
€22.80 (449.30% Upside)
Blogger Sentiment
Bullish
DE:1KPA Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth €772.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
52.50%
12-Months-Change
Fundamentals
Return on Equity
-38.70%
Trailing 12-Months
Asset Growth
13.86%
Trailing 12-Months
Company Description
Protara Therapeutics, Inc.
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
1KPA Stock 12 Month Forecast
Average Price Target
€22.80
▲(449.30% Upside)
Technical Analysis
Protalix
―
TuHURA Biosciences
―
Skye Bioscience
―
Orchestra BioMed Holdings
―
Zura Bio
―
Options Prices
Currently, No data available
---